Marginum develops tissue recognition technology specifically for oncological surgery to improve patient outcomes. Their solution enables precise, non-invasive detection of cancerous tissue during procedures, minimizing damage to healthy structures. This technology assists surgeons by providing safe and efficient tissue monitoring without disrupting established surgical workflows.
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
During cancer surgery, accurately identifying cancerous tissues while minimizing damage to healthy tissues remains a significant challenge. Current methods may lack precision, potentially leading to incomplete tumor removal or excessive tissue resection. This can result in increased risk of recurrence and complications for patients.
Solution
Marginum is developing fluorescence-guided aspirate tissue monitoring technology to enhance the precision and safety of cancer surgery. Their system allows surgeons to accurately identify cancerous tissue in real-time without disrupting existing surgical workflows. The technology utilizes fluorescence to differentiate between healthy and cancerous tissues, providing surgeons with enhanced visualization and control during tissue removal. This approach aims to improve surgical outcomes by ensuring complete tumor removal while preserving healthy tissue, ultimately leading to better patient outcomes and reduced risk of complications.
Target Audience
The primary target audience includes oncological surgeons and hospitals seeking to improve the precision and efficacy of cancer surgery.
Features
- Fluorescence-guided imaging for real-time tissue differentiation
- Minimally invasive aspirate tissue monitoring
- Integration with existing surgical workflows
- Enhanced visualization of cancerous tissue margins
- Quantitative assessment of tissue characteristics